Through the recent coronavirus crisis, the UK’s pharmaceutical sector has performed strongly and delivered innovation at a time when it was most needed. In this article, Dr Cheryl Teoh discusses how the industry has been set up for success.
AS THE YEAR progresses, 2020 continues to bring rapid and unexpected changes to our way of life. The way we work has potentially been transformed and fundamental questions are being raised relating to how economies should function. However, this upheaval has not deterred the UK’s pharmaceutical industry; instead, it has delivered in the most challenging of circumstances. Even amid the chaos of COVID-19, pharma has shown great innovation and collaboration at a time when it is most needed.
The crisis has seen the sector come together on a huge scale. Trade secrets and intellectual property have been more widely shared in recent months than ever before, with the development of a successful vaccine for COVID-19 becoming the industry’s new holy grail. Under immense pressure, many companies have also accelerated digitalisation processes, allowing for clinical trial data to be processed and shared faster than ever.1
However, the UK’s pharmaceutical sector has a long-running track record of delivering powerful innovation that overwhelmingly predates the pandemic. This progress is a testament to the way the sector has been developed and nurtured in the UK, providing a blueprint for how to create a truly cutting-edge industry. In my view, there are three major factors driving this long-running phenomenon in UK pharma: a dynamic supply chain, government support and value chains.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
The first factor driving innovation in the sector is the UK’s dynamic supply chain, connecting institutions from all parts of society. The country is home to many of the world’s best universities and therefore a natural hub for talented graduates. Having access to highly talented PhD and master’s students is a significant boost for the pharmaceutical sector, especially compared to countries that are more reliant on immigration to supply the workforce for pharmaceutical firms. Recent boosts to apprenticeship training in vaccine manufacturing also represent a welcome move as vaccine development becomes a key focus across the sector.
The UK’s National Health Service (NHS) plays an important role in the broader pharmaceutical supply chain”
However, universities also play another key role – many of the most successful firms began as start-ups spun out of university research faculties. One prominent example is Abcam, which has become one of the leading players in the sector due to its work on antibodies. The company was initially spun out of a genetics research institute in Cambridge. These firms can also benefit from the local wealth of knowledge around mergers and acquisitions (M&As) and intellectual property, driving further growth.
The UK’s National Health Service (NHS) plays an important role in the broader pharmaceutical supply chain, providing the ideal infrastructure for the commercialisation of drugs. Working with pharmaceutical companies, the NHS contributes significantly to UK pharma’s strong international competitiveness. It also plays a critical role in supporting clinical trials. For example, hospitals in Birmingham are home to many of the UK’s leading clinical research institutions and have supported work on ground-breaking medicines.2
Government support
The second key factor driving the UK’s pharmaceutical innovation is a system of government support that incentivises risk taking. Government incentives have continued to drive business activity and productivity, with the Future Fund, Sustainable Innovation Fund and many others forming part of a broader strategy aimed at cementing the UK as a global science superpower.
One area that particularly supports the pharmaceutical sector is the system of R&D tax credits, whereby tax relief can be claimed on activities throughout the drug development process, from drug discovery through to post-launch trials. It can be claimed on expenditure on a wide range of areas, including employee costs, with the salaries of the Chief Scientific Officer and other R&D personnel eligible for claims. It also applies to materials directly used to carry out R&D and the utilities and software costs needed to support these activities.
Given the importance of R&D for the pharmaceutical industry, this form of tax relief represents a major boost. The relief pays out generously, with the qualifying costs multiplied by 230 percent to provide a reduction in businesses’ corporation tax bill. In other words, for every £100 spent on qualifying R&D costs, the company can lower its corporation tax bill by a further £130 in addition to the £100 spent.3 For these companies, who face the reality that most drug prospects will not make it to market, the tax relief makes a significant difference and encourages inventiveness and risk taking.
Furthermore, in line with the UK’s ambition to raise R&D investment and earmark the UK as a continued global life science hub, organisations such as the Bio Industry Association support their members through efforts that encourage Foreign Direct Investment and streamlining of regulatory, legal and financial incentives for domestic and international companies. These efforts span public and private industry ecosystems and impact both large and small players in the market. For example, smaller biotech firms in a significant loss position, which would previously have been disqualified from receiving state funding due to state aid rules, can now benefit. The government has also increased its support, ensuring that R&D tax relief payments are processed and paid within rapid timeframes in order to assist firms seeking to accelerate growth during the crisis.
Value chains
Thirdly, the industry is set up in a way that creates and protects value and the financial outlook for the sector is therefore strong, even against the backdrop of COVID-19. Indeed, even at the peak of the pandemic, global investment in biotech continued to soar, reaching new heights in Q2. This was driven by a string of deep-pocketed US initial public offerings (IPOs) in biopharma and cell and gene therapy. In the UK, financing has also remained positive in recent months, driven by later-stage private fundraising deals and follow-on public market financing rounds.4
Broadly speaking, the UK’s pharmaceutical and life sciences sector has held up well in the face of the crisis, with robust capitalisation providing a structure for continued momentum despite the downturn. Driving this relatively strong performance is a backdrop of innovation, aided by a complex and wide-ranging network of government support, financial incentives and collaboration with research institutions and the NHS.
Despite huge uncertainty across global economies in 2020, the UK’s innovative pharmaceutical industry has sustained its strength”
For example, one well-publicised exit included Mercia portfolio company The Native Antigen Company, now a world-leading supplier of antigen reagents required for antibody testing kits. The company has been a key player in previous efforts against emerging viruses like Zika. Now acquired by LGC, a leader in genomics analysis, the deal highlights how competitive marketplaces and firm technology-investor foundations can support steady long-term valuations and drive continued deal flow despite wider headwinds.
Conclusion
Despite huge uncertainty across global economies in 2020, the UK’s innovative pharmaceutical industry has sustained its strength, driven by a flexible investment landscape and dynamic support networks. The wide-ranging web of support from the government has created an industry landscape that links the NHS with research institutions, private companies and universities, fostering a virtuous cycle of innovation that boosts the whole sector.
Even during the current crisis, this approach has proven its worth. The COVID-19 pandemic acted as a catalyst for new ways of working in the sector, which may ultimately result in the vaccine the world needs during this time. While all countries have their own unique circumstances, aspects of the UK’s model may offer valuable lessons about how the pharmaceutical sector – and innovative industries in general – can be supported to boost economic growth and encourage the development of cutting-edge solutions to address the challenges of tomorrow.
About the author
Dr Cheryl Teoh is a Senior Technical Consultant at global innovation funding consultancy, Leyton UK. She holds a PhD in Biomaterials, with a professional background in scientific innovation. She joined Leyton UK’s team of sector experts in August 2018 and has helped numerous businesses benefit from valuable innovation tax schemes, including R&D.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.